Plus Therapeutics Inc (PSTV)

Jun 06, 2025

Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks

Jun 06, 2025

Jun 05, 2025

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - Revista ADVFN

Jun 05, 2025

Jun 05, 2025

Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa

Jun 05, 2025

Jun 05, 2025

Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com

Jun 05, 2025

Jun 05, 2025

PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus

Jun 05, 2025

Jun 05, 2025

PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus

Jun 05, 2025

Jun 03, 2025

Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks

Jun 03, 2025

Jun 02, 2025

Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus

Jun 02, 2025

Jun 01, 2025

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jun 01, 2025

May 31, 2025

Plus: Q1 Earnings Snapshot - New Haven Register

May 31, 2025

May 30, 2025

Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks

May 30, 2025

May 30, 2025

Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus

May 30, 2025

May 30, 2025

Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com

May 30, 2025

May 30, 2025

Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 30, 2025

May 30, 2025

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus

May 30, 2025

May 30, 2025

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times

May 30, 2025

May 30, 2025

PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 30, 2025

May 28, 2025

Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister

May 28, 2025

May 27, 2025

DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail

May 27, 2025

May 25, 2025

3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail

May 25, 2025

May 24, 2025

Plus Therapeutics recives Nasdaq delinquency notice - MSN

May 24, 2025

May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus

May 23, 2025

May 23, 2025

Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus

May 23, 2025

May 23, 2025

Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks

May 23, 2025

May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus

May 23, 2025

May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire

May 23, 2025

May 23, 2025

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - TradingView

May 23, 2025

May 23, 2025

SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail

May 23, 2025

May 20, 2025

Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN

May 20, 2025

May 19, 2025

Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks

May 19, 2025

May 19, 2025

Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail

May 19, 2025

May 17, 2025

Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail

May 17, 2025

May 15, 2025

Plus Therapeutics Delays Quarterly Report Filing - TipRanks

May 15, 2025

May 15, 2025

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN

May 15, 2025

May 14, 2025

Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria

May 14, 2025

May 14, 2025

Plus Therapeutics (PSTV) Showcases Promising REYOBIQ Data at Con - GuruFocus

May 14, 2025

May 14, 2025

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in - GuruFocus

May 14, 2025

May 14, 2025

Plus Therapeutics Presents Promising ReSPECT Trial Data on REYOBIQ for Leptomeningeal Metastases at 2025 Nuclear Medicine and Neurooncology Conference - Nasdaq

May 14, 2025

May 14, 2025

Plus Therapeutics reports progress in CNS cancer therapy - Investing.com

May 14, 2025

May 14, 2025

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and - GlobeNewswire

May 14, 2025

May 14, 2025

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - TradingView

May 14, 2025

May 14, 2025

Plus Therapeutics (PSTV) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025

May 13, 2025

Leptomeningeal Metastases Pipeline 2025: Key Companies, MOA, - openPR.com

May 13, 2025

May 08, 2025

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire

May 08, 2025

May 07, 2025

Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World

May 07, 2025

May 06, 2025

Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World

May 06, 2025

May 05, 2025

Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus

May 05, 2025

May 05, 2025

Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com

May 05, 2025